Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562820 · ClinicalTrials.gov registry record · Phase 1
An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome
A Phase 1 study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02562820 is a Phase 1 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 4 participants.
The verdict
NCT02562820, a Phase 1 study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Rett Syndrome (RTT) is a complex disorder resulting from mutations in a gene encoding the MeCP2 protein. Currently, there are no methods to fix the abnormal gene, however, animal studies suggest that the symptoms of RTT can be treated. Ketamine is a sedative or anesthetic, depending on the dose. The drug is approved by the US Food and Drug Administration (FDA) and is commonly used in children and adults. Animal studies and case reports in humans suggest that ketamine may reduce the symptoms of Rett syndrome. The purpose of this study is to determine the safety and efficacy of ketamine for treating breathing and behavioral symptoms of RTT.
Interventions
- PROCEDURE Intravenous infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02562820
The ClinicalTrials.gov registry entry for NCT02562820 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous infusion is the first listed.
NCT02562820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02562820 about?
NCT02562820 is a clinical study titled "An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome". Rett Syndrome (RTT) is a complex disorder resulting from mutations in a gene encoding the MeCP2 protein. Currently, there are no methods to fix the abnormal gene, however, animal studies suggest that the symptoms of RTT can be treated. Ketamine is a sedative or anesthetic, depending on the dose. Th...
What is the current status of trial NCT02562820?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-11. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02562820?
The interventions under investigation include: Intravenous infusion (PROCEDURE).
Who is sponsoring clinical trial NCT02562820?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.